Q3 2025 NRX Pharmaceuticals Inc Earnings Call Transcript
Key Points
- NRX Pharmaceuticals Inc (NRXP) has made transformative progress in developing its business, advancing drug approval applications for KETAFREE, NRX-100, and NRX-101.
- The company has expanded its NRX-101 pipeline and closed on multiple acquisition targets for a network of interventional psychiatric clinics under HOPE Therapeutics.
- NRX Pharmaceuticals Inc (NRXP) is generating revenue from its clinics and anticipates strong growth as it integrates and expands its clinic network.
- The company holds rights to more than 70 patents related to the use of DCS in treating depression, PTSD, and other brain disorders.
- NRX Pharmaceuticals Inc (NRXP) has secured operating capital sufficient to fund drug development operations through 2026, strengthening its balance sheet.
- NRX Pharmaceuticals Inc (NRXP) reported a loss of operations of $4 million for the third quarter, an increase from the previous year.
- The company's revenue for the third quarter was relatively modest at $240,000, reflecting only 22 days of operations from a single clinic group.
- There are uncertainties regarding the FDA's approval process for NRX-100 and NRX-101, including the timing of potential approvals.
- The company faces challenges in ensuring adequate domestic supply if the FDA moves to ban preservative-containing formulations of ketamine.
- NRX Pharmaceuticals Inc (NRXP) may need to build a sales force or partner with larger commercial partners to effectively market NRX-100 and NRX-101 upon approval.
Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals Q3 2025 earnings conference call. (Operator Instructions) This call is being recorded on Monday, November 17, 2025.
I would now like to turn the conference over to Matthew Duffy, Chief Business Officer. Please go ahead.
Thank you, Joelle, and welcome, everyone. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under US federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ statements made on this call is contained in our periodic reports filed with the SEC.
The forward-looking statements made during this call speak only as of the date hereof and the company undertakes no obligation to update or revise
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
